( NASDAQ-NMS:VNDA )

News from Vanda Pharmaceuticals Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Sep 13, 2017, 16:04 ET Vanda's Tradipitant Improves Itch and Disease Severity in Patients with Atopic Dermatitis

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced results from an 8-week randomized Phase II clinical study of tradipitant as a...


Sep 11, 2017, 17:00 ET Vanda Pharmaceuticals Announces Participation at September 2017 Investor Conferences

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that it will participate at the following upcoming investor conferences in...


Sep 06, 2017, 17:00 ET Vanda Pharmaceuticals Announces Participation at the Citi 12th Annual Biotech Conference

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that it will participate at the Citi 12th Annual Biotech Conference. Vanda will...


Aug 02, 2017, 16:01 ET Vanda Pharmaceuticals Reports Second Quarter 2017 Financial Results

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced financial and operational results for the second quarter ended June 30,...


Jul 21, 2017, 07:00 ET Vanda Receives Negative Opinion for Marketing Authorization from the European Medicines Agency on Fanaptum™ for the Treatment of Schizophrenia

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) announced today that the European Medicines Agency's Committee for Medicinal Product for Human...


Jul 17, 2017, 09:00 ET Vanda Pharmaceuticals to Announce Second Quarter 2017 Financial Results on August 2, 2017

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it will release results for the second quarter of 2017 on Wednesday, August 2,...


Jun 05, 2017, 17:00 ET Vanda Pharmaceuticals Announces Participation at June 2017 Investor Conferences

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that it will participate at the following upcoming investor conferences in June...


May 02, 2017, 16:01 ET Vanda Pharmaceuticals Reports First Quarter 2017 Financial Results

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial and operational results for the first quarter ended March 31,...


May 01, 2017, 17:45 ET Vanda Pharmaceuticals to Present at the Deutsche Bank 42nd Annual Health Care Conference

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that it will deliver a corporate presentation at the Deutsche Bank 42nd Annual...


Apr 13, 2017, 16:45 ET Vanda Pharmaceuticals to Announce First Quarter 2017 Financial Results on May 2, 2017

Conference Call and Webcast to Follow Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it will release results for the first...


Mar 29, 2017, 17:40 ET Vanda and UCSF Announce License Agreement for CFTR Activators and Inhibitors

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) announced today that it has entered into a license agreement with UC San Francisco (UCSF), under...


Mar 06, 2017, 16:05 ET Vanda Pharmaceuticals Announces Participation at March 2017 Investor Conferences

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that it will participate at the following upcoming investor conferences in March...


Feb 15, 2017, 16:01 ET Vanda Pharmaceuticals Reports Fourth Quarter 2016 and Full Year 2016 Financial Results

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial and operational results for the fourth quarter and full year ended...


Jan 19, 2017, 16:30 ET Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2016 Financial Results on February 15, 2017

Conference Call and Webcast to Follow Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it will release results for the fourth...


Jan 09, 2017, 07:00 ET Vanda Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2016 Revenue Results and 2017 Financial Guidance

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of novel therapies...


Dec 07, 2016, 18:45 ET Vanda Pharmaceuticals Settles Fanapt® Patent Litigation with Apotex

Vanda Grants Apotex a license to sell generic Fanapt® beginning November 2027 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it...


Nov 14, 2016, 17:00 ET Vanda Pharmaceuticals Announces Participation at November 2016 Investor Conferences

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that it will participate at the following upcoming investor conferences in...


Nov 02, 2016, 16:01 ET Vanda Pharmaceuticals Reports Third Quarter 2016 Financial Results

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial and operational results for the third quarter ended September 30,...


Oct 24, 2016, 16:01 ET Vanda Pharmaceuticals Settles Fanapt® Patent Litigation with Taro

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it has entered into a License Agreement (the License Agreement) with Taro...


Oct 12, 2016, 16:30 ET Vanda Pharmaceuticals to Announce Third Quarter 2016 Financial Results on November 2, 2016

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it will release results for the third quarter of 2016 on Wednesday, November 2,...


Aug 30, 2016, 15:00 ET USPTO Dismisses Petition for Inter Partes Review of Fanapt® Patent

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that the United States Patent and Trademark Office (USPTO) Patent Trials and...


Aug 25, 2016, 14:51 ET Vanda Patents Found Valid and Infringed in Fanapt® ANDA Litigation

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that Judge Gregory M. Sleet of the United States District Court for the...


Aug 01, 2016, 07:00 ET HETLIOZ® is Now Available for the Treatment of Non-24-Hour Sleep-Wake Disorder in Germany

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that HETLIOZ® (tasimelteon) is now available for the treatment of...


Jul 27, 2016, 16:01 ET Vanda Pharmaceuticals Reports Second Quarter 2016 Financial Results

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial and operational results for the second quarter ended June 30,...


Jul 12, 2016, 16:30 ET Vanda Pharmaceuticals to Announce Second Quarter 2016 Financial Results on July 27, 2016

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it will release results for the second quarter of 2016 on Wednesday, July...